Skip to content

A Study to Explore the Effect of Moringa Oleifera (E-HS-01) on Flow Mediated Dilatation and Hemodynamics

A Randomized, Double-blind, Cross-over, Placebo Controlled Study to Explore the Effect of Moringa Oleifera (E-HS-01) on Flow Mediated Dilatation and Hemodynamics

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05002881
Enrollment
60
Registered
2021-08-12
Start date
2021-08-16
Completion date
2022-03-31
Last updated
2022-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Function

Brief summary

The present study is designed to evaluate the modulatory effect of IP on the vascular endothelial function. To assess its vasodilatation potential, change in flow mediated dilation (FMD) and blood flow velocity (BFV) will be assessed in healthy adult male population.

Interventions

OTHERMoringa oleifera (E-HS-01)

One capsule to be taken stat

OTHERPlacebo

One capsule to be taken stat

Sponsors

Vedic Lifesciences Pvt. Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Double-blind, Cross-over

Intervention model description

Randomized, Double-blind, Cross-over, Placebo controlled study

Eligibility

Sex/Gender
MALE
Age
20 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

1. Healthy, physically active male volunteers aged between 20 to 35 years. 2. Body mass index (BMI) ≥ 20 and ≤ 29.9 kg/m2. 3. Participants with low to moderate physical activity as defined by a six-point scale score of ≥1 to ≤ 4. 4. Participants with systolic blood pressure (SBP) ≤ 139 and diastolic blood pressure (DBP) ≤ 89 mm Hg. 5. Ability to read and provide written, personally signed, and dated informed consent to participate in the study. 6. Ready to abstain from alcohol, caffeine, and vigorous physical activity (as assessed by six point scale) for 24 hours prior to every study visit. 7. Ready to abstain from beet root, moringa, and spinach for 48 hours prior to every study visit.

Exclusion criteria

1. Participants with history of pulmonary disorders (asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pneumonia, etc) 2. Participants having fasting blood glucose (FBG) levels ≥ 125 mg/dL. 3. Participants currently on/or having history of taking antihypertensives / diuretics. 4. Smokers and tobacco users. 5. Participants with heavy alcohol consumption, defined as more than 14 standard alcoholic drink (SAD)/week or more than 4 SAD in a day. (NOTE - A standard alcoholic drink contains approximately 14 grams of alcohol, which is equivalent to 12 ounces of beer (\ 5% alcohol), 8.5 ounces of malt liquor (\ 9% alcohol), 5 ounces of wine (\ 12% alcohol), 3.5 ounces of fortified wine (e.g., sherry or port), or 1.5 ounces of liquor (distilled spirits; \ 40% alcohol). 6. Participants currently on performance enhancing supplements. 7. History/symptoms of coronary artery disease, myocardial infarction etc. 8. Participants with any other condition which in the view of the investigator is likely to interfere with the study or put the participants at risk.

Design outcomes

Primary

MeasureTime frameDescription
Percent flow mediated dilatationFrom baseline (pre-IP administration) to 3 hours post-IP administrationTo determine change in the endothelial function after single dose administration of Moringa oleifera as assessed by the change in the Percent flow mediated dilatation of brachial artery, from baseline (pre-IP administration) to 3 hours post IP administration, in comparison to the placebo.

Secondary

MeasureTime frameDescription
Blood flow velocityat baseline (pre-IP administration) and at 1, 2, and 3 hours post-IP administrationThe endothelial function can be assessed by measuring changes in blood flow by intravascular ultrasound. It has been demonstrated that biophysical forces such as flow-derived forces, modulates the vascular structure and function. Endothelium is mechanotransducer, which senses mechanical forces on its surface and the transduces these signals into biochemical signals. There exists a large body of literature regarding the wide spectra of biological signals induced by blood flow in the endothelium.18 Thus to evaluate the effect of Moringa oleifera on hemodynamics, change in blood flow velocity (cm/seconds) will be assessed at baseline (pre-IP administration) and at 1, 2, and 3 hours post-IP administration will be measured.
Percent flow mediated dilatationat 1, and 2 hours post-IP administration from baseline (pre-IP administration)To identify the onset of effect of the investigational product, the flow mediated dilation at 1, and 2 hours post-IP administration from baseline (pre-IP administration) will be assessed as a secondary outcome.

Countries

India

Contacts

Primary ContactDr. Shalini Dr. Srivastava, MD - Medicine
shalini.s@vediclifesciences.com022 42172326
Backup ContactMr. Zubair Ansari, M pharm
zubair@vediclifesciences.com7738945639

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026